Quantum Surgical has agreed to acquire NeuWave Medical, the former Johnson & Johnson subsidiary known for its microwave ablation technology, in a move that broadens the French medtech company’s reach in minimally invasive cancer treatment. The transaction, announced on February 24, 2026, brings together Quantum’s Epione robotic platform and NeuWave’s installed base in the U.S., where the acquired company says its technology is used in more than 70% of leading cancer centers. Financial terms were not disclosed, but both the company statement and follow-up media coverage present the deal as a significant step in Quantum Surgical’s expansion beyond its home market.
Deal Expands Quantum Surgical’s Clinical Footprint
At the center of the transaction is a clear industrial logic: NeuWave contributes a widely adopted microwave ablation offering, while Quantum Surgical adds robotic guidance designed to improve the planning and execution of percutaneous tumor ablation procedures. Quantum says Epione has already treated more than 1,400 patients in Europe and the United States, giving the company a growing procedural base to build on as it integrates a complementary therapy platform. Taken together, the two businesses are positioning themselves around a more complete offering for interventional oncology, especially in image-guided, minimally invasive tumor care.
New Parent Company Takes Shape
Rather than merging directly into a single operating business, Quantum Surgical and NeuWave will remain separate subsidiaries under a newly created parent company, Precision IO Group Inc. According to the announcement and media reports, the new group will be led by medtech executive Kurt Azarbarzin and based in Miami, with a broader ambition to build a global platform focused on precision procedures and interventional radiology. This structure suggests the companies are aiming to preserve continuity for customers while creating room for shared commercialization, technology development, and future scale.
Remote Procedures Become a Central Theme
A notable part of the announcement is its emphasis on remote-enabled care, which Quantum Surgical describes as a future development priority for the new group. The company says it is working on remote intervention capabilities that would allow experts to support trajectory planning and review outcomes from a distance, potentially widening access to specialist expertise without requiring patients to travel. That message was echoed in third-party commentary, including a LinkedIn analysis that framed the acquisition as a way to pair NeuWave’s market penetration with Quantum’s robotic precision in support of more distributed cancer care.
Competitive and Market Context
The deal also arrives after a period of strategic repositioning around NeuWave inside Johnson & Johnson’s portfolio. MedTech Dive reported that J&J had informed customers in 2025 that it planned to discontinue the NeuWave business before later confirming it had received a binding offer from Quantum, indicating that the acquisition may also provide continuity for clinicians already using the technology. For Quantum Surgical, that creates an opportunity to enter the U.S. market with greater traction, while for existing NeuWave users it reduces the risk of disruption by keeping the product line active under a new owner focused specifically on cancer intervention.
This acquisition matters because it is more than a simple asset purchase: it combines a robotics-driven treatment platform with an established ablation technology already embedded in major U.S. oncology centers. The result is a more credible commercial and clinical proposition for Quantum Surgical as it seeks to expand from a promising specialist player into a broader interventional oncology group with international ambitions. If execution matches the strategy outlined in the announcement, Precision IO Group could emerge as a more visible force in robotic-assisted tumor ablation and the next phase of remote-enabled cancer procedures.